TOP | BTB Therapeutics

Bench To Bedside

We develop novel therapeutic drugs by translating the ideas and discoveries in basic research.

Bedside To Bench

We perform R&D with the aim for tackling unmet medical needs.

Beyond Traditional Benchmark

We conduct drug development research based on evaluation
metrics that differ from traditional benchmarks.

We conduct drug development research based on evaluation metrics that differ from traditional benchmarks.

Borderless Translational Biology

We promote interdisciplinary collaboration across
different hospital departments and academic fields.

Bundling Transdisciplinary Branches

We coordinate the launch of new drugs in clinical trials by
working across various hospital departments and academic settings.

We coordinate the launch of new drugs in clinical trials by working across various hospital departments and academic settings.

Breeding Therapeutic Breakthroughs

We perform R&D with the attitude of constantly delivering
new knowledge in the world.

We perform R&D with the attitude of constantly delivering new knowledge in the world.

NEWS

2024.8.2

Press

Election of Representative Director and Chief Executive Officer
2024.7.1

Topics

Notice of Relocation of Headquarters
2024.6.24

Press

We have received an investment from SMBC Venture Capital. With this financing we will accelerate the development of our pipeline, especially the clinical development of ENDOPIN, a non-opioid analgesic compound.
*Click here for details
2024.6.17

Press

Announcement: Appointment of Chief Financial Officer and Representative Director
We are pleased to announce that Dr. Takashi Kiyoizumi has been appointed as Representative Director and Chief Financial Officer, effective June 10, 2024, in addition to Representative Director Dr. Tsuyoshi Ogiku.
*Click here for details
2024.4.30

Press

The press release from Kyoto University Hospital regarding the start of the Phase II part of an investigator-initiated clinical trial for a new analgesic drug was published.
*Click here for the press release by Kyoto University Hospital. (Japanese only)
2023.10.27

Topics

At the general meeting of shareholders held on October 17, 2023, a resolution was passed to elect the following director.
Takashi Kiyoizumi, Director (U.S. Development) (New Appointment)
2023.10.27

Topics

We have received an investment from Innovation Kyoto 2021 Investment Limited Partnership with Kyoto University Innovation Capital Corporation (Kyoto iCAP) as a partner with unlimited liability.
With this investment, we will promote research and development of next-generation cancer immunotherapeutics and rare disease therapeutics (genetic diseases) with a focus on novel pain medications for further growth.
*Click here for press release by Kyoto iCAP (Japanese only)
2023.10.05

Topics

Our part-time director, Prof. Masatoshi Hagiwara, Department of Anatomy and Developmental Biology, Kyoto University, has received the Special Award from the Japanese Society of Toxicology.(Japanese only)
2023.07.28

Topics

We have been selected by the Japan Agency for Medical Research and Development (AMED) for the FY2023 "Drug Discovery Venture Ecosystem Enhancement Project (Drug Discovery Venture Open Call)" (2nd round). Under this project, we will begin full-scale development of our product in the United States.
Title: Development of ENDOPIN, an oral analgesic that activates the descending pain suppression pathway
Click here to see the selected proposals. (Japanese only)
2023.04.18

Topics

The website of BTB Drug Development Research Center has been updated.
The company logo has been renewed.